Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Natco
28 tablet
Sofosbuvir 400mg + Daclatasvir 60mg
Keep in cold place
Delivering To:
Overview
A combination medication called Hepcinat Plus 60mg/400mg Tablet is used to treat chronic hepatitis C virus (HCV) infection. It functions by slowly removing the hepatitis C virus from the blood and lowering the quantity of the virus in the body. Daclatasvir and Sofosbuvir are the active ingredients in Hepcinat Plus tablets.
Hepatitis C
Treatment of Chronic hepatitis C virus (HCV) infection
The majority of adverse effects go away as your body becomes used to the medication and don't need to be treated. If they continue or you're concerned about them, speak with your doctor.
Common side effects of Hepcinat Plus are: Fatigue
Nausea
Headache
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush, or break it. Hepcinat Plus 60mg/400mg Tablet may be taken with or without food, but it is better to take it at a fixed time.
A combination of two medications is Hepcinat Plus 60mg/400mg Tablet. Antiviral drugs include daclatasvir and sofosbuvir. They function by slowly removing the hepatitis C virus from the blood and reducing its load in the body. A protein known as NS5A, which is necessary for the hepatitis C virus to replicate, is inhibited by the direct-acting antiviral drug daclatasvir. Another direct-acting antiviral drug, sofosbuvir, functions by blocking NS5B, a distinct protein that is also necessary for the hepatitis C virus to replicate. Its efficacy in treating HCV is increased by these.
Alcohol
unsafe
It is typically not advised to consume alcohol while using Hepcinat Plus tablets
Pregnancy
consult your doctor
It's unclear if Hepcinat Plus tablets are safe to take while pregnant. Before taking this drug, pregnant women should discuss their pregnancy status with their healthcare professional.
Breast Feeding
consult your doctor
Breastfeeding women should speak with their doctor before using Hepcinat Plus tablets because it is unknown if they are eliminated in human breast milk.
Driving
danger
If a patient has any adverse effects that could make it unsafe for them to drive or operate machinery, they should always keep an eye on how they are responding to the Hepcinat plus tablet medicine.
Kidney
caution
Do not take Sofosbuvir And Daclatasvir tablets without a doctor's consultation in case of kidney problems.
Liver
caution
Hepatitis C symptoms may worsen as a result of alcohol's detrimental effects on the liver.
It is advisable not to miss a dose of Sofosbuvir And Daclatasvir tablets. If you miss a scheduled dose of this medicine, contact your doctor immediately.
Patients with renal disease can take Hepcinat Plus tablets; however, depending on their kidney function, the dosage may need to be changed. During treatment, patients with severe kidney disease might need to be closely watched. In most situations, hepatitis C can be cured with Hepcinat Plus tablets. However, a number of factors, including the virus's genotype, how severe the liver damage is, and the patient's general health, affect how well the treatment works.
Patients with cirrhosis brought on by hepatitis C may utilize Hepcinat Plus tablets. However, depending on the severity of the cirrhosis and other factors, the course of treatment might need to be altered. Patients with cirrhosis usually need to be closely monitored.
Patients with HIV who also have hepatitis C can utilize the Hepcinat Plus medication. However, further monitoring could be necessary, and the treatment plan might be different from that for people with hepatitis C alone.
Elderly people can utilize Hepcinat Plus tablets. However, depending on factors including liver and kidney function as well as other medical issues, the course of therapy might need to be changed. Elderly people may need close observation while undergoing treatment.
Patients with renal disease can take Hepcinat Plus tablets; however, depending on their kidney function, the dosage may need to be changed. During treatment, patients with severe kidney disease might need to be closely watched.
ANRS Compassionate-Use Cohort Study (2019). Daclatasvir plus sofosbuvir ± ribavirin in HIV–HCV coinfection and advanced cirrhosis. Journal of Viral Hepatitis.
D. B. et al. (2019). Daclatasvir plus sofosbuvir, with or without ribavirin, in real‑world patients with HIV‑HCV coinfection and advanced liver disease. Journal of Viral Hepatitis.
Elsayed, A., et al. (2025). Predictors of response to sofosbuvir plus daclatasvir in HCV‑infected patients with stage 4 and 5 chronic kidney disease and maintenance hemodialysis. Egyptian Journal of Internal Medicine, 37, 12.
Farrag, A. N., & Kamel, A. M. (2024). Efficacy of 8‑week daclatasvir‑sofosbuvir regimen in chronic hepatitis C: A systematic review and meta‑analysis. Virology Journal, 21, 275.
Khan, R., et al. (2023). Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection: a NEJM trial. New England Journal of Medicine, 368(1), 34–44.
Reyna et al. (2023). Daclatasvir plus sofosbuvir with or without ribavirin in hepatitis C genotype‑3 cirrhosis: a real‑life 24‑week study. Annals of Hepatology.
